Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development Targeting Molecular Glue Degraders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RBM39 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | RBM39 Full-Length & Domain Truncations (RRM1, RRM2, RRM3, Pro-Rich). High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. Includes resistance mutants (G268V, R287H, R293H). | View RBM39 Products |
| E3 Ligase Complex | DCAF15-DDB1 Complex Protein. For ternary complex formation assays. HEK293 expressed. | View DCAF15 Products |
| Gene Delivery | RBM39 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and degradation reporters. | View RBM39 Products |
| Benchmark Ab | Anti-RBM39 (C-terminal) Recombinant Rabbit Monoclonal. For IP/Western, target engagement. | View RBM39 Products |
| Validator | RBM39 siRNA Set (3 target-specific duplexes). For knockdown verification and specificity controls. | View RBM39 Products |
| Related Target A | DCAF15 — E3 Ligase Substrate Receptor Essential for RBM39 Ternary Complex Formation. | View DCAF15 Products |
| Related Target B | DDB1 — Core Component of CUL4-DDB1 Ubiquitin Ligase Complex. | View DDB1 Products |
| Related Target C | SF3B1 — Splicing Factor Partner; Synergy Studies with RBM39 Degradation. | View SF3B1 Products |
| Related Target D | GSPT1 — Alternative Molecular Glue Target for Selectivity Profiling. | View GSPT1 Products |
| Related Target E | RBM38 — Paralog RNA-Binding Protein for Off-Target Counter-Screening. | View RBM38 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Formation Assay (SPR/TR-FRET) | Purified RBM39 Full-Length & RRM Domain (WT & Mutants) + DCAF15-DDB1 Complex. >95% purity, sequence verified. |
| Drug Resistance Screening | RBM39 resistance mutants (G268V, R287H, R293H) provided as high-purity recombinant proteins for structure-activity relationship studies. |
| Selectivity vs. RRM Family Paralogs | RBM38, RBM4, RB10 homolog panel proteins strictly verified by mass spec for off-target screening. |
| Target Engagement & Degradation in Cells | High-specificity Anti-RBM39 antibody (C-terminal) for IP/MS; validated siRNA included for specificity checks. |
| Cell Line Construction | Lentivirus-based stable RBM39-overexpression lines for degradation reporter assays (HiBiT, NanoLuc). |
Global Clinical Landscape & Future Outlook
The race for RBM39 therapeutics centers on molecular glue degraders (sulfonamides like indisulam and E7820) that hijack the CRL4ⁱDCAF15 E3 ubiquitin ligase complex to degrade RBM39, causing lethal splicing defects in cancer cells. As first-generation agents reach the clinic, resistance mutations in RBM39 (G268V, R287H, R293H in RRM2 domain) have emerged, driving the field toward rationally designed next-generation molecular glues with improved selectivity over GSPT1 and optimized cooperativity. Combination strategies with SF3B1 inhibitors, BCL-2 inhibitors, and other agents are under active investigation to maximize synthetic lethality in myeloid malignancies (AML, MDS) and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue (Sulfonamide) | Eisai, Bayer, Daiichi Sankyo, Dialectic Therapeutics | AML, MDS, Solid Tumors | Ternary Complex Assay (Need purified RBM39 + DCAF15-DDB1) |
| Covalent Binders / PROTAC | Emerging Biotech, Academic Programs | Refractory Cancers | Selectivity Assay (Need Mutant vs WT RBM39) |
| Splicing Modulators | Astellas (H3B-8800), Daiichi Sankyo | Myeloid Malignancies | Splicing Reporter Assay (Need functional RRM proteins) |
Live RBM39 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Key Resistance Mutations & Functional Domains
RBM39 contains three RNA recognition motifs (RRM1, RRM2, RRM3) and a proline-rich region. Resistance to indisulam-class molecular glues primarily arises from mutations in RRM2 (G268V, R287H, R293H) that disrupt the drug-binding interface without affecting RNA binding. dbSNP variant rs1803701 (also annotated in UniProt) may represent natural polymorphism. TarMart provides recombinant mutant proteins to enable resistance mechanism profiling.